Doximity (DOCS) Stock Trades Up, Here Is Why [Yahoo! Finance]
Doximity, Inc. Class A (DOCS)
Company Research
Source: Yahoo! Finance
Sales improved significantly, driven by robust platform engagement, particularly in new products like AI-powered workflow tools and the expanded client portal. The improved engagement facilitated upselling among top pharma clients. Doximity recorded an impressive 56% adjusted EBITDA margin, highlighting disciplined cost management, which was supported by higher incremental margins from digital products. The business is observing stabilization in key markets, including strong growth in pharma budgets and increased adoption of digital solutions. Guidance was also strong as the company lifted its full-year sales outlook, while the EBITDA forecast came in ahead of consensus. Zooming out, we think this was a strong quarter for the company. Following the result, Keybanc analyst Scott Schoenhaus upgraded the stock's rating from Neutral to Buy on hopes for momentum to improve heading into the last quarter of the year. Is now the time to buy Doximity? Access our full analysis report
Show less
Read more
Impact Snapshot
Event Time:
DOCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DOCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DOCS alerts
High impacting Doximity, Inc. Class A news events
Weekly update
A roundup of the hottest topics
DOCS
News
- Doximity, Inc. (NASDAQ: DOCS) had its price target raised by analysts at JPMorgan Chase & Co. from $30.00 to $48.00. They now have a "neutral" rating on the stock.MarketBeat
- Zacks.com featured highlights Doximity, Impinj and Innodata [Yahoo! Finance]Yahoo! Finance
- TikTok ‘dermfluencers' have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week [Yahoo! Finance]Yahoo! Finance
- TikTok ‘dermfluencers' have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week [Fortune]Fortune
- Polen U.S. Small Company Growth Strategy Exited Doximity (DOCS) Due to Multiple Factors [Yahoo! Finance]Yahoo! Finance
DOCS
Earnings
- 11/7/24 - Beat
DOCS
Sec Filings
- 11/15/24 - Form 4
- 11/15/24 - Form 4
- 11/14/24 - Form SC
- DOCS's page on the SEC website